Physician profile
William Noyes
NPI 1649382292
$1,856,434.35
in general payments reported to CMS, 2019-2025
81 companies · $4,805 in 2025
The $4,805 reported for 2025 was more than what 95% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $798K · 2021: $369K · 2022: $682K · 2023: $962 · 2024: $1,786 · 2025: $4,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,179 · Travel and Lodging: $2,322 · Gift: $52.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,178.83 |
| Travel and Lodging | $2,321.52 |
| Gift | $52.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,846,491.11 | 2020-2022 | |
| Onmark, INC. | $3,408.01 | 2025 | |
| US Oncology Corporate, INC. | $841.68 | 2024 | |
| Janssen Biotech, INC. | $540.92 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $372.27 | 2019-2025 | Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $371.14 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $317.91 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $235.65 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $224.03 | 2019-2023 | Adcetris |
| Novartis Pharmaceuticals Corporation | $195.47 | 2019-2025 | |
| Lilly USA, LLC | $176.55 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $160.61 | 2020-2025 | |
| Pharmaessentia USA Corporation | $145.99 | 2022-2025 | Besremi |
| Incyte Corporation | $120.64 | 2020-2025 | Zynyz, Monjuvi, Jakafi |
| Astellas Pharma US INC | $119.49 | 2020-2025 | Vyloy, Xospata, Xtandi |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Noyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.